2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007060678v1 19/1/182    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, C. A. Articles by Erdmann, E. Search for Related Content PubMed PubMed Citation Articles by Schneider, C. A. Articles by Erdmann, E. Related Collections Related Articles

Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease

Christian A. Schneider^*, Ele Ferrannini, Ralph DeFronzo, Guntram Schernthaner, John Yates^|| and Erland Erdmann^*

^* Klinik III für Innere Medizin, University of Cologne, Cologne, Germany; Department of Internal Medicine and CNR Institute of Clinical Physiology, University of Pisa, Pisa, Italy; Diabetes Division, University of Texas Health Science Center, San Antonio, Texas; Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria; and ^|| Takeda Global Research and Development Center, Inc., Deerfield, Illinois

Correspondence: Dr. Christian A. Schneider, Facharzt für Innere Medizin/Kardiologie Klinik III für Innere Medizin, Zimmer 0, C, 329 Universität zu Köln Kerpener Strasse 68, 50937 Köln, Germany. Phone: 0221-4786205; Fax: 0221-4783673; E-mail. christian.schneider{at}uk-koeln.de

Received for publication June 18, 2007. Accepted for publication August 27, 2007.

Patients with diabetes and chronic kidney disease (CKD) are at particularly high risk for cardiovascular disease (CVD). This post hoc analysis from the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) investigated the relationship between CKD and incident CVD in a population of patients with diabetes and documented macrovascular disease, as well as the effects of pioglitazone treatment on recurrent CVD. CKD, defined as an estimated GFR <60 ml/min per 1.73m², was present in 597 (11.6%) of 5154 patients. More patients with CKD reached the primary composite end point (all-cause mortality, myocardial infarction (MI), stroke, acute coronary syndrome, coronary/carotid arterial intervention, leg revascularization, or amputation above the ankle) than patients without CKD (27.5 versus 19.6%; P < 0.0001). Patients with CKD were also more likely to reach a secondary composite end point (all-cause mortality, MI, and stroke). Patients who had CKD and were treated with pioglitazone were less likely to reach the secondary end point (hazard ratio 0.66; 95% confidence interval 0.45 to 0.98), but this association was not observed among those with better renal function. In addition, there was a greater decline in estimated GFR with pioglitazone (between-group difference 0.8 ml/min per 1.73 m²/yr) than with placebo. In conclusion, CKD is an independent risk factor for cardiovascular events and death among patients with diabetes and preexisting macrovascular disease. Patients who had CKD and were treated with pioglitazone were less likely to reach a composite end point of all-cause death, MI, and stroke, independent of the severity of renal impairment.

Related Articles

Cardiovascular Disease, Chronic Kidney Disease, and Type 2 Diabetes Mellitus: Proceeding with Caution at a Dangerous Intersection

Takeshi Kanda, Shu Wakino, Koichi Hayashi, and Jorge Plutzky
J. Am. Soc. Nephrol. 2008 19: 4-7. [Full Text] [PDF]

This article has been cited by other articles:

				J. Odom, B. Williamson, and L. Carter Rosiglitazone and pioglitazone in the treatment of diabetes mellitus Am. J. Health Syst. Pharm., October 1, 2008; 65(19): 1846 - 1850. [Full Text] [PDF]

				C. Abaterusso, A. Lupo, V. Ortalda, V. De Biase, A. Pani, M. Muggeo, and G. Gambaro Treating Elderly People with Diabetes and Stages 3 and 4 Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1185 - 1194. [Abstract] [Full Text] [PDF]

				D. J. Betteridge, R. A. DeFronzo, and R. J. Chilton PROactive: time for a critical appraisal Eur. Heart J., April 2, 2008; 29(8): 969 - 983. [Abstract] [Full Text] [PDF]

				G. Schernthaner Kidney disease in diabetology: lessons from 2007 Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1112 - 1115. [Full Text] [PDF]

				T. Kanda, S. Wakino, K. Hayashi, and J. Plutzky Cardiovascular Disease, Chronic Kidney Disease, and Type 2 Diabetes Mellitus: Proceeding with Caution at a Dangerous Intersection J. Am. Soc. Nephrol., January 1, 2008; 19(1): 4 - 7. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673